Abstract
The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre-and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.
Keywords: Prostate cancer, androgen receptor, abiraterone, enzalutamide.
Current Drug Targets
Title:New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Volume: 17 Issue: 3
Author(s): Rita Assi, Sally Temraz, Ali Shamseddine and Deborah Mukherji
Affiliation:
Keywords: Prostate cancer, androgen receptor, abiraterone, enzalutamide.
Abstract: The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre-and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.
Export Options
About this article
Cite this article as:
Assi Rita, Temraz Sally, Shamseddine Ali and Mukherji Deborah, New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450116666150907101044
DOI https://dx.doi.org/10.2174/1389450116666150907101044 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives
Letters in Drug Design & Discovery Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Bioengineering of Bacterial Magnetic Particles and their Applications in Biotechnology
Recent Patents on Biotechnology 8-Azapurine Nucleus: A Versatile Scaffold for Different Targets
Mini-Reviews in Medicinal Chemistry Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry A Review of Maternal and Fetal Growth Factors in Diabetic Pregnancy
Current Diabetes Reviews Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals
Anti-Cancer Agents in Medicinal Chemistry Targeting the mTOR Pathway in Tumor Malignancy
Current Cancer Drug Targets Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry Recent Progress in the Development of Fluorometric Chemosensors to Detect Enzymatic Activity
Current Medicinal Chemistry Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Current Gene Therapy Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Anti-neoplastic and Calcium modulatory action of Caffeic acid phenethyl ester and Dasatinib in C6 glial cells: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Unfolded Protein Response is Involved in Trans-Platinum (II) Complex-Induced Apoptosis in Prostate Cancer Cells via ROS Accumulation
Anti-Cancer Agents in Medicinal Chemistry Opioids Resistance in Chronic Pain Management
Current Neuropharmacology Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging Does the Oxazolidinone Derivatives Constitute a Functional Approach for Cancer Therapy?
Clinical Cancer Drugs